MedTrace Logo

Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients

NCT06238388 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-08-20

No results posted yet for this study

Summary

This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.

Conditions

  • Chronic Kidney Disease Patients

Interventions

DRUG

HSK21542 Injection

A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-10
Primary Completion
2023-11-21
Completion
2024-02-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238388 on ClinicalTrials.gov